Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam versus best available therapy for serious infections caused by MBL-producing multidrug-resistant Gram-negative bacteria
2017-004544-38Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aztreonam + avibactam in bacterial disease (2 arms), sponsored by Pfizer. Primary endpoint: Clinical cure at test of cure in the micro-ITT population. Started Jun 2020; status: terminated.
02
Drugs
aztreonam + avibactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2017-004544-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004544-38.